|Articles|March 8, 2017
Tufts CSDD Releases Results of New Impact Report
A recently completed study reported that the 505(b)(2) approval pathway for new drug applications in the US has not led to shorter approval times.
Advertisement
A recently completed study conducted by Tufts CSDD reported that the 505(b)(2) approval pathway for new drug applications in the US, aimed at avoiding the duplication of studies performed on a previously approved drugs, has not led to shorter approval times.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Breaking the Efficacy Ceiling in IBD and Beyond
2
The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research
3
ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program
4
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
5